Codiak BioSciences logo
Codiak BioSciences CDAK
report update icon

Quarterly report 2022-Q3
added 05-16-2026

Codiak BioSciences Gross Profit | CDAK

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Codiak BioSciences

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 2.92 K - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.92 K 2.92 K 2.92 K

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
Precision BioSciences Precision BioSciences
DTIL
24.3 M $ 6.31 0.16 % $ 80.9 M usaUSA
Dyadic International Dyadic International
DYAI
177 K $ 0.45 0.31 % $ 16.3 M usaUSA
Editas Medicine Editas Medicine
EDIT
1.63 M $ 2.79 6.49 % $ 248 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
311 K $ 3.91 1.3 % $ 22.2 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
41.9 M $ 12.6 0.93 % $ 269 K usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
9 K $ 2.62 0.69 % $ 121 M israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
42.7 M $ 55.62 0.47 % $ 1.5 B usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-241 K $ 0.4 3.54 % $ 3.15 M israelIsrael
Exelixis Exelixis
EXEL
935 M $ 58.85 0.79 % $ 16 B usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
28.6 M $ 3.15 0.62 % $ 231 K usaUSA
Fate Therapeutics Fate Therapeutics
FATE
2.43 M $ 2.43 4.74 % $ 289 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
31 M $ 2.09 2.96 % $ 58.3 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
20 M $ 10.62 4.12 % $ 303 M usaUSA
Merus N.V. Merus N.V.
MRUS
-17.7 M - - $ 5.78 B niderlandNiderland
Geron Corporation Geron Corporation
GERN
2.44 M $ 1.21 0.83 % $ 807 M usaUSA
Gilead Sciences Gilead Sciences
GILD
17.8 B $ 144.63 0.85 % $ 180 B usaUSA
Genmab A/S Genmab A/S
GMAB
-182 M $ 38.48 10.73 % $ 2.49 B danmarkDanmark
GeoVax Labs GeoVax Labs
GOVX
883 K $ 0.32 1.31 % $ 307 K usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
2.79 B $ 7.41 1.37 % $ 5.04 B spainSpain
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
23.6 B $ 46.55 0.93 % $ 189 B britainBritain
GT Biopharma GT Biopharma
GTBP
27 K $ 6.16 0.98 % $ 34 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
150 M $ 108.31 2.73 % $ 13 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
39.5 M $ 14.31 0.77 % $ 12.3 B chinaChina
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
670 M $ 39.92 0.71 % $ 2.3 B usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
114 M $ 0.37 6.44 % $ 61.7 M usaUSA
iBio iBio
IBIO
2.17 M $ 1.12 0.89 % $ 117 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
11.4 M $ 9.75 1.56 % $ 88 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-7.24 M $ 1.68 0.58 % $ 113 M germanyGermany
Immutep Limited Immutep Limited
IMMP
1.87 M $ 4.27 0.46 % $ 6.22 B australiaAustralia
Immuron Limited Immuron Limited
IMRN
4.77 M $ 1.07 0.46 % $ 247 M australiaAustralia
Innate Pharma S.A. Innate Pharma S.A.
IPHA
23.8 M $ 1.58 1.28 % $ 142 M franceFrance
Incyte Corporation Incyte Corporation
INCY
2.04 B $ 114.13 0.06 % $ 22.3 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
1.71 M $ 1.33 0.01 % $ 5.54 M canadaCanada
INmune Bio INmune Bio
INMB
-10.9 K $ 1.94 0.52 % $ 48 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
40.6 M $ 1.15 2.05 % $ 53.9 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
112 M $ 103.83 2.33 % $ 20.7 B usaUSA
Innoviva Innoviva
INVA
308 M $ 20.64 0.68 % $ 1.39 B usaUSA